MAZE Files 8-K: Press Release Furnished for Q2 2025 Earnings

Rhea-AI Filing Summary

Maze Therapeutics, Inc. reported that on August 12, 2025 it issued a press release reporting its financial results for the second quarter ended June 30, 2025. The filing states the full text of that press release is furnished as Exhibit 99.1 to this Current Report. The Company notes that the information in Item 2.02, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or subject to certain liabilities under the Securities Act. The Form 8-K identifies the registrant as Maze Therapeutics, Inc., lists its Nasdaq trading symbol MAZE, shows Delaware as its jurisdiction of incorporation, and indicates it is an emerging growth company.

Positive

• Press release reporting Q2 2025 results was furnished as Exhibit 99.1, providing investors with a designated disclosure mechanism.
• Company details and listing are clear: registrant identified, Nasdaq ticker MAZE, and emerging growth company status indicated.

Negative

• No financial figures or tables are included in the body of this Form 8-K; the filing references a press release but does not present the results directly.
• The press release is explicitly furnished, not filed, which the company notes limits certain statutory liabilities and incorporation by reference.

Insights

Securities Analyst

TL;DR: Routine Form 8-K furnishing a Q2 2025 earnings press release; the filing contains no financial figures and the release is furnished, not filed.

The filing explicitly states that Maze issued a press release on August 12, 2025 reporting results for the quarter ended June 30, 2025 and that the press release is furnished as Exhibit 99.1. The 8-K does not include numerical results or tables within the body of the report. The company also clarifies the press release is not "filed" for Section 18 purposes, which is a standard legal statement minimizing certain post-filing liabilities. For investors seeking substantive financial metrics, this filing points to an external exhibit rather than providing the figures directly in the 8-K text.

Corporate Governance Expert

TL;DR: Administrative disclosure consistent with standard practice; exhibits furnished rather than filed, and the report is signed by the company secretary.

The 8-K documents a routine disclosure event: a press release reporting quarterly results furnished as an exhibit. The form confirms corporate details (jurisdiction, Nasdaq listing under MAZE) and indicates the company is an emerging growth company. The signature block shows the report was executed by Courtney Phillips, General Counsel and Corporate Secretary, on August 12, 2025. The explicit statement that the exhibit is furnished and not filed is a common governance/legal provision and limits incorporation-by-reference and certain liabilities.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000184229500018422952025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Maze Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42490	82-2635018
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
171 Oyster Point Blvd., Suite 300
South San Francisco, California				94080
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 850-5070

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock - par value $0.001 per share		MAZE		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Maze Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the second quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the date hereof, except as expressly set forth by reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1*		Press Release dated August 12, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	August 12, 2025	By:	/s/ Courtney Phillips
			Courtney Phillips General Counsel and Corporate Secretary

FAQ

What did Maze Therapeutics (MAZE) disclose in this Form 8-K?

Maze Therapeutics disclosed that on August 12, 2025 it issued a press release reporting financial results for the quarter ended June 30, 2025; the press release is furnished as Exhibit 99.1.

Does this Form 8-K include the company’s Q2 2025 financial numbers?

No. The 8-K states the press release reporting results is furnished as Exhibit 99.1; the filing text itself does not include numerical financial figures.

Is the press release considered "filed" under the Securities Exchange Act?

No. The filing explicitly states the information and Exhibit 99.1 are furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or certain Securities Act liabilities.

What is Maze’s ticker and corporate jurisdiction listed in the filing?

Ticker: MAZE on Nasdaq; Jurisdiction: Delaware.

Who signed the Form 8-K for Maze Therapeutics?

Courtney Phillips, General Counsel and Corporate Secretary, signed the report on August 12, 2025.